Patents by Inventor Dmitri Bobilev

Dmitri Bobilev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies for treating cancer
    Patent number: 12156872
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: December 3, 2024
    Assignees: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • METHODS OF TREATING CANCER WITH ANTI-TIM-3 ANTIBODIES
    Publication number: 20240301057
    Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.
    Type: Application
    Filed: February 2, 2024
    Publication date: September 12, 2024
    Inventors: Dmitri BOBILEV, Andrew R. FERGUSON, Kristen Anne MCEACHERN, Jing Yu WANG
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20240226082
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 11, 2024
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereof
    Publication number: 20240158495
    Abstract: The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
    Type: Application
    Filed: January 12, 2023
    Publication date: May 16, 2024
    Inventors: Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King, Dmitri Bobilev, Srimoyee Ghosh, Baochuan Huang, David Jenkins
  • Methods of treating cancer with anti-TIM-3 antibodies
    Patent number: 11926665
    Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 12, 2024
    Assignee: TESARO, INC.
    Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
  • ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF
    Publication number: 20220135670
    Abstract: The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 5, 2022
    Inventors: Helen Toni Jun, Marilyn Kehry, Peter Bowers, David J. King, Dmitri Bobilev, Srimoyee Ghosh, Baochuan Huang, David Jenkins
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20200289493
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 17, 2020
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • METHODS OF TREATING CANCER WITH ANTI-TIM-3 ANTIBODIES
    Publication number: 20190322746
    Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.
    Type: Application
    Filed: January 9, 2018
    Publication date: October 24, 2019
    Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang